Home
Resources
Diseases
COVID-19
Hepatitis B
Human papillomavirus (HPV)
Malaria
Measles
Mpox
Pneumococcal disease
RSV (Respiratory syncytial virus)
Compendium
Hexavalent vaccines
HPV vaccines
Malaria vaccines
PCV vaccines
RSV vaccines
Training
Vaccine Portfolio Optimization and Prioritization (VPOP)
Evaluation
The Tool
The Tutorial
The Dashboard
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Type of publications
Guidelines (40)
NITAG documentation (1641)
Reports (63)
SAGE documentation (226)
Scientific publications (122)
Systematic reviews (SYSVAC) (3100)
Regions
Africa (297)
Americas (794)
Eastern Mediterranean (58)
Europe (744)
Global (1)
South-East Asia (82)
Western Pacific (216)
Diseases
Chikungunya (13)
Cholera (35)
COVID-19 (1589)
Cytomegalovirus (1)
Dengue (43)
Diphtheria (90)
Ebola (19)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (71)
Hepatitis A (69)
Hepatitis B (171)
Hepatitis C (5)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (77)
HIV / AIDS (10)
Human papillomavirus (HPV) (537)
Influenza (629)
Japanese encephalitis (34)
Lyme disease, Borreliosis (2)
Malaria (33)
Measles (144)
Meningococcal disease (155)
Moraxella catarrhalis (1)
Mpox (58)
Mumps (50)
Pertussis (120)
Pneumococcal disease (305)
Poliomyelitis (94)
Q fever (1)
Rabies (33)
Rotavirus (121)
RSV (Respiratory syncytial virus) (69)
Rubella (69)
Salmonella (3)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (71)
Tick-borne encephalitis (14)
Tuberculosis (83)
Typhoid (32)
Varicella (77)
Yellow fever (44)
Zika (1)
Show more
5192 results found
2025
∙
Jefferson Jones
Proposed clinical considerations for clesrovimab
2025
∙
Danielle Moulia
Evidence to Recommendations Framework: Clesrovimab
2025
∙
Susan Hills
Clinical guidance for use of virus-like particle chikungunya vaccine in pregnant and breastfeeding women
2025
∙
Susan Hills
Surveillance for adverse events following use of live attenuated chikungunya vaccine and its use among travelers
2025
∙
J Erin Staples
Evidence to Recommendations and proposed recommendations for use of virus-like particle chikungunya vaccine among laboratory workers
2025
∙
Susan Hills
Evidence to Recommendations and proposed recommendations for use of virus-like particle chikungunya vaccine among adolescent and adult travelers
2025
∙
Conseil Supérieur de la Santé (CSS)
Vaccination against chikungunya in Belgium
2025
∙
NACI
NACI Statement on seasonal influenza vaccines for 2025–2026
2025
∙
Health Council of the Netherlands
COVID-19 vaccination in 2025 in the Netherlands
2025
∙
Health Council of the Netherlands
RSV vaccination for the elderly
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register
